Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology detailed a four-year vesting stock option inducement grant for its newly appointed Chief Financial Officer.

Rhea-AI Summary

Olema Oncology (OLMA) granted employment inducement stock options to new Chief Financial Officer Jason V. O’Byrne in connection with his appointment effective August 11, 2026.

The award covers 650,000 shares of common stock, granted on September 1, 2026 with an exercise price of $10.56 per share, equal to the last reported sale price on that date. The options were approved by the Compensation Committee under Olema’s 2022 Inducement Plan and are subject to Nasdaq Listing Rule 5635(c)(4). Vesting occurs over four years: 25% on August 11, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, conditional on continuous employment.

News Explained

Olema granted its CFO options covering 650,000 common shares, but the shares are subject to four-year, continued-employment vesting; existing ownership can be diluted only if the options vest and are then exercised.

Argus Sep 3 session 1 alert

-0.92% close to close 0.9x rel. volume Open Argus

Details

News Market Reaction – OLMA

$964.22M Mkt Cap at Peak Alert

On Sep 3, the first trading day after this news, OLMA closed 0.92% below the previous close.

Data tracked by StockTitan Argus for the Sep 3 session.

Key Figures

Option shares: 650,000 shares Exercise price: $10.56 per share Effective grant date: September 1, 2026 +5 more

Option shares

650,000 shares

CFO employment inducement award

Exercise price

$10.56 per share

Equal to Nasdaq-reported sale price on September 1, 2026

Effective grant date

September 1, 2026

Stock option award

CFO effective date

August 11, 2026

Jason V. O’Byrne appointment

Vesting period

Four years

Stock options, subject to continuous employment

Initial vesting

25 percent

Vesting on August 11, 2027

Initial vesting date

August 11, 2027

First vesting date

Remaining installments

36 equal monthly installments

Following the initial 25 percent vesting

Historical Context

5 past events · Latest: Aug 31

5 events

1. Aug 31

   Investor conference

   24h Move

   +1.3%

   Company announced participation in three September investor conferences in New York.

2. Aug 13

   CFO appointment

   24h Move

   +0.7%

   Jason O’Byrne became CFO as the company approached pivotal OPERA-01 data.

3. Aug 10

   Second-quarter earnings

   24h Move

   -12.6%

   Quarterly net loss widened amid higher research and corporate spending.

4. Aug 04

   Inducement grant

   24h Move

   -1.5%

   Options covering 254,540 shares were granted to seven new employees.

5. Jul 02

   Inducement grant

   24h Move

   +1.0%

   Options covering 215,800 shares were granted to eight new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement award, exercise price, nasdaq listing rule 5635(c)(4)

3 terms

inducement award financial

"The Company granted Mr. O’Byrne an employment inducement award"

An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.

exercise price financial

"with an effective grant date of September 1, 2026 and an exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O’Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O’Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company’s common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 1, 2026. The award was approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan. The stock options vest over four years, with 25 percent vesting on August 11, 2027 and the remainder vesting in 36 equal monthly installments over the following three years, subject to continuous employment as of such vesting dates.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option inducement grant did Olema Oncology (OLMA) give its new CFO?

Olema Oncology granted Jason V. O’Byrne an employment inducement award of stock options to purchase 650,000 shares of common stock. The options were granted on September 1, 2026 with an exercise price of $10.56 per share under the 2022 Inducement Plan.

What are the vesting terms of Jason V. O’Byrne’s Olema Oncology (OLMA) stock options?

The stock options vest over four years. 25% vest on August 11, 2027, and the remaining 75% vest in 36 equal monthly installments over the next three years, subject to Mr. O’Byrne’s continuous employment.

Why did Olema Oncology (OLMA) disclose the CFO inducement grant under Nasdaq Rule 5635(c)(4)?

The company stated it is providing details of the inducement stock option grant in accordance with Nasdaq Listing Rule 5635(c)(4), which governs equity awards made as a material inducement to a person entering employment.

What is the exercise price of the Olema Oncology (OLMA) inducement options granted on September 1, 2026?

The exercise price of the inducement stock options is $10.56 per share, equal to the last reported sale price of Olema’s common stock on the Nasdaq market on September 1, 2026.